Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo transdermal patch Clear all
Completed Not applicable Interventional Results available

Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery

NCT03120351
View directory record Official record
Conditions
Perioperative Chest Pain
Interventions
Lidoderm 5 % Topical Patch, Placebo patch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

NCT02859142
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 11, 2026, 11:49 PM EDT
Terminated Phase 2 Interventional Results available

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

NCT00957034
View directory record Official record
Conditions
Heart Failure
Interventions
placebo, testosterone
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 11, 2026, 11:49 PM EDT
Not listed Phase 1 Interventional

Nicotine Treatment of Mild Cognitive Impairment (MCI)

NCT00091468
View directory record Official record
Conditions
Age-Related Memory Disorders
Interventions
Transdermal nicotine patch, Placebo transdermal patch
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Results available

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 11, 2026, 11:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women

NCT01633814
View directory record Official record
Conditions
Menopause, Aging, Blood Pressure
Interventions
Transdermal estradiol, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

NCT00946192
View directory record Official record
Conditions
Exercise-related Amenorrhea
Interventions
Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
Drug · Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 11, 2026, 11:49 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

Memory Improvement Through Nicotine Dosing (MIND) Study

NCT02720445
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Nicotine Transdermal Patch, Placebo Patch
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
36
States / cities
Scottsdale, Arizona • North Little Rock, Arkansas • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 11, 2026, 11:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery

NCT00790829
View directory record Official record
Conditions
Postoperative Pain
Interventions
transdermal nicotine patch
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 11, 2026, 11:49 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

NCT07353021
View directory record Official record
Conditions
Anxiety, Sleep
Interventions
Active dermal patch, Placebo patch
Device
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 3 Interventional Results available

Sancuso® for Gastroparesis: An Open Label Study.

NCT01989221
View directory record Official record
Conditions
Gastroparesis
Interventions
Sancuso®
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline for Smoking Cessation - 1

NCT00439413
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Selegiline Transdermal Patch, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
College Park, Maryland • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747
View directory record Official record
Conditions
Schizophrenia
Interventions
Transdermal Nicotine Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524
View directory record Official record
Conditions
Tobacco Use Disorder, Schizophrenia
Interventions
sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking
Behavioral · Drug · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

NCT00013585
View directory record Official record
Conditions
Cognition Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 11, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch, Blood Flow and Oxidative Stress Study

NCT00954096
View directory record Official record
Conditions
Healthy
Interventions
transdermal nicotine patch (7mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2009 · Synced Sep 11, 2026, 11:49 PM EDT